Lifestar Pharma Llcc/o Rxcrossroads Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Lifestar Pharma Llcc/o Rxcrossroads Pharmaceutical Import Records from India — 5 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lifestar Pharma Llcc/o Rxcrossroads — Pharmaceutical Importer Profile (2026) | 5 Products, $1.6M Trade | TransData Nexus

Lifestar Pharma Llcc/o Rxcrossroads

Pharmaceutical Importer · United States · Antibiotics Focus · $1.6M Total Trade · DGFT Verified

Lifestar Pharma Llcc/o Rxcrossroads is a pharmaceutical importer based in United States with a total trade value of $1.6M across 5 products in 5 therapeutic categories. Based on 37 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Lifestar Pharma Llcc/o Rxcrossroads sources from 1 verified Indian supplier, with Mankind Pharma Limited accounting for 100.0% of imports.

Lifestar Pharma Llcc/o Rxcrossroads — Import Portfolio & Supplier Network

Lifestar Pharma Llcc/o Rxcrossroads import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Lifestar Pharma Llcc/o Rxcrossroads?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mankind Pharma Limited	$2.5M	119	100.0%

Lifestar Pharma Llcc/o Rxcrossroads sources from 1 verified Indian supplier across 79 distinct formulations. The sourcing is highly concentrated — Mankind Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Tobramycin inhalation solution, USP 300MG/5 ML 56x5ml ( qty.972 packs) net conent of 16.3296 kg of bulk drug) batch	$150.0K	3
Tobramycin inhalation solution, USP 300MG/5 ML 56x5ml (qty.1296 packs) net conent 21.7728 kg of bulk drug) batch no.	$150.0K	3
Ttobramycin inhalation solution USP 300MG/4 ML ( qty.492 packs) net conent of8.2656 kg of bulk drug) batch no.	$150.0K	3
Ttobramycin inhalation solution USP 300MG/5 ML 56x5ml ( qty.648 packs) net conent of 10.8864 kg of bulk drug) batch	$128.4K	3
Arformoterol tartrate inhalation solution 15 MCG/2 ML (0.015 MG/2 ML) 60x2ml sterile unit-dose vials (15x4 unit dose	$100.0K	2
Arformoterol tartrate inhalation solution 15 MCG/2 ML (0.015 MG/2 ML) 30x2ml sterile unit-dose vialsbatch no. 693w005	$50.0K	1
Arformoterol tartrate inhalation solution 15 MCG/2 ML (0.015 MG/2 ML) 30x2ml sterile unit-dose vials batch no. 693w006	$50.0K	1
Arformoterol tartrate inhalation solution 15 MCG/2 ML (0.015 MG/2 ML) 30x2ml sterile unit-dose vials batch no. 693w004	$50.0K	1
Nitrofurantoin capsules USP (macrocrystals) 25MG 100ct. batch no. epx001 mfg. date jan-2024 exp date	$50.0K	1
Nitrofurantoin capsules USP (monohydrate/macrocrystals) 100 MG 100 ct batch no.at2x003 mfg. date jan-2024 exp date	$50.0K	1
Nitrofurantoin capsules USP (monohydrate/macrocrystals) 100 MG 100 ct batch no.at2x004 mfg. date jan-2024 exp date	$50.0K	1
Nitrofurantoin capsules USP (monohydrate/macrocrystals) 100 MG 100 ct batch no.at2x005 mfg. date jan-2024 exp date	$50.0K	1
Phenylephrine hydrochloride ophthalmic solution, USP 2.5%, 15ML batch no. b6x003mfg. date mar-2024 exp date	$50.0K	1
Phenylephrine hydrochloride ophthalmic solution, USP 2.5%, 15ML batch no. b6x004mfg. date mar-2024 exp date	$50.0K	1
Phenylephrine hydrochloride ophthalmic solution, USP 2.5%, 15ML batch no. b6x005mfg. date mar-2024 exp date	$50.0K	1

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tobramycin	Antibiotics	$600.0K	12	1.5%	13
2	Nitrofurantoin	Advanced Antibiotics	$400.0K	8	1.2%	12
3	Formoterol	Respiratory	$300.0K	6	0.5%	19
4	Nitroglycerin	Cardiovascular	$155.6K	8	1.6%	13
5	Phenylephrine	Respiratory & OTC	$150.0K	3	0.2%	8

Lifestar Pharma Llcc/o Rxcrossroads imports 5 pharmaceutical products across 5 categories into United States totaling $1.6M.

Lifestar Pharma Llcc/o Rxcrossroads — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lifestar Pharma LLC, operating under the auspices of Mankind Pharma Limited, is a U.S.-based pharmaceutical importer and distributor specializing in finished pharmaceutical formulations. Established in 2016, Lifestar Pharma is headquartered in Mahwah, New Jersey. As a subsidiary of Mankind Pharma, one of India's leading pharmaceutical companies, Lifestar Pharma plays a pivotal role in delivering affordable, high-quality generic medicines to the U.S. market.

Mankind Pharma Limited, founded in 1991 and headquartered in New Delhi, India, is renowned for its extensive portfolio spanning various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, and respiratory diseases. The company has a significant presence in over 25 countries, underscoring its global reach and commitment to accessible healthcare.

In the United States, Lifestar Pharma serves as a crucial conduit for Mankind Pharma's products, ensuring that high-quality generics are accessible to a broader patient population. By leveraging Mankind Pharma's robust manufacturing capabilities and research and development expertise, Lifestar Pharma contributes to the diversification and affordability of the U.S. pharmaceutical supply chain.

2Distribution Network

Lifestar Pharma LLC operates its distribution network from its headquarters in Mahwah, New Jersey. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic positioning in New Jersey provides advantageous access to major U.S. ports and transportation hubs. This facilitates efficient distribution across the United States and potentially to neighboring regions.

The proximity to key logistics infrastructure enables Lifestar Pharma to maintain a responsive and agile supply chain, ensuring timely delivery of pharmaceutical products to meet market demands. However, detailed information regarding their geographic coverage beyond the United States is not readily available.

3Industry Role

Lifestar Pharma LLC functions as a pharmaceutical importer and distributor within the United States. By sourcing finished pharmaceutical formulations from its parent company, Mankind Pharma Limited, and other suppliers, Lifestar Pharma plays a significant role in enhancing the diversity and affordability of the U.S. pharmaceutical market. Its operations contribute to the availability of high-quality generic medicines, thereby supporting the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Lifestar Pharma Llcc/o Rxcrossroads

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lifestar Pharma's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.6 million USD from India across 37 shipments, all sourced from Mankind Pharma Limited. This single-source dependency indicates a strategic choice to leverage Mankind Pharma's established manufacturing capabilities and product portfolio.

The consistent volume of shipments suggests a stable and reliable relationship between Lifestar Pharma and Mankind Pharma. However, this concentration also presents potential risks, such as supply chain disruptions due to unforeseen events affecting the sole supplier. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

Lifestar Pharma's supply chain resilience is closely tied to its exclusive partnership with Mankind Pharma Limited. While this relationship ensures access to a wide range of pharmaceutical formulations, the lack of backup suppliers may pose challenges in the event of supply chain disruptions. The limited number of formulations imported (79 unique formulations) suggests a focused product strategy, which could be advantageous in maintaining quality control but may limit flexibility in responding to market changes.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the approval and monitoring of pharmaceutical products. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs, ensuring their safety, efficacy, and quality.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for drug approval and regulation. The Drug Enforcement Administration (DEA) also regulates controlled substances, impacting certain pharmaceutical imports.

For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic drugs meet the same standards of quality, strength, and dosage form as their brand-name counterparts.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. market are stringent. Manufacturers must register with the FDA and comply with Current Good Manufacturing Practice (CGMP) regulations, which are aligned with international standards such as EU GMP, WHO GMP, and PIC/S. These standards ensure that pharmaceutical products are consistently produced and controlled according to quality standards.

Lifestar Pharma Llcc/o Rxcrossroads — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Lifestar Pharma's product strategy focuses on high-barrier generic medicines across diverse dosage forms, including ophthalmics, injectables, inhalation solutions, and oral solids. This approach addresses the market demand for affordable alternatives to complex and specialty drugs, catering to a broad patient base. The emphasis on scientific rigor and regulatory excellence ensures that these products meet the stringent standards required for the U.S. market.

2Sourcing Profile

Lifestar Pharma's sourcing strategy is centered on high-quality, difficult-to-manufacture products, leveraging the capabilities of its parent company, Mankind Pharma Limited. This focus on complex generics allows Lifestar Pharma to offer differentiated products in the U.S. market, meeting the needs of patients requiring specialized treatments. India's robust pharmaceutical manufacturing infrastructure and adherence to international quality standards make it a strategic partner for Lifestar Pharma's sourcing needs.

3Market Positioning

Lifestar Pharma serves the U.S. pharmaceutical market by providing high-quality generic medicines, particularly in complex therapeutic areas. Its product mix positions the company to cater to segments such as retail pharmacies, hospitals, and government tenders, offering affordable alternatives to brand-name drugs. By focusing on high-barrier generics, Lifestar Pharma differentiates itself in the competitive U.S. market, addressing the demand for specialized and cost-effective treatments.

Seller's Guide — How to Become a Supplier to Lifestar Pharma Llcc/o Rxcrossroads

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Lifestar Pharma, given the company's focus on high-quality, complex generics. Suppliers that can meet the stringent quality standards and regulatory requirements of the U.S. market are well-positioned to collaborate with Lifestar Pharma. Identifying gaps in Lifestar Pharma's current sourcing, such as unmet therapeutic needs or emerging market demands, can provide avenues for new suppliers to enter the partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Lifestar Pharma and the U.S. market must adhere to FDA regulations, including obtaining an ANDA approval for each product. Manufacturers must comply with CGMP standards, which are recognized internationally, including EU GMP, WHO GMP, and PIC/S. Additionally, products must meet FDA labeling requirements, including the use of English language and compliance with the Drug Facts labeling format.

3How to Approach

Frequently Asked Questions — Lifestar Pharma Llcc/o Rxcrossroads

What products does Lifestar Pharma Llcc/o Rxcrossroads import from India?

Lifestar Pharma Llcc/o Rxcrossroads imports 5 pharmaceutical products across 5 categories. Top imports: Tobramycin ($600.0K), Nitrofurantoin ($400.0K), Formoterol ($300.0K), Nitroglycerin ($155.6K), Phenylephrine ($150.0K).

Who supplies pharmaceuticals to Lifestar Pharma Llcc/o Rxcrossroads from India?

Lifestar Pharma Llcc/o Rxcrossroads sources from 1 verified Indian suppliers. The primary supplier is Mankind Pharma Limited (100.0% of imports, $2.5M).

What is Lifestar Pharma Llcc/o Rxcrossroads's total pharmaceutical import value?

Lifestar Pharma Llcc/o Rxcrossroads's total pharmaceutical import value from India is $1.6M, based on 37 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Lifestar Pharma Llcc/o Rxcrossroads focus on?

Lifestar Pharma Llcc/o Rxcrossroads imports across 5 categories. The largest: Antibiotics (37.4%), Advanced Antibiotics (24.9%), Respiratory (18.7%).

Get Full Lifestar Pharma Llcc/o Rxcrossroads Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.